These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10852128)

  • 1. Targeted cytokines for cancer immunotherapy.
    Lode HN; Reisfeld RA
    Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What to do with targeted IL-2.
    Lode HN; Xiang R; Perri P; Pertl U; Lode A; Gillies SD; Reisfeld RA
    Drugs Today (Barc); 2000 May; 36(5):321-36. PubMed ID: 12861355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
    Lode HN; Xiang R; Duncan SR; Theofilopoulos AN; Gillies SD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8591-6. PubMed ID: 10411920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.
    Becker JC; Varki N; Gillies SD; Furukawa K; Reisfeld RA
    J Clin Invest; 1996 Dec; 98(12):2801-4. PubMed ID: 8981927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytokines: a new approach to immunotherapy of melanoma.
    Reisfeld RA; Becker JC; Gillies SD
    Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytokines: a promising approach to cancer immunotherapy.
    Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
    Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
    Pancook JD; Becker JC; Gillies SD; Reisfeld RA
    Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-cytokine fusion proteins for the therapy of cancer.
    Helguera G; Penichet ML
    Methods Mol Med; 2005; 109():347-74. PubMed ID: 15585931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
    Zeng Y; Jiang J; Huebener N; Wenkel J; Gaedicke G; Xiang R; Lode HN
    Cancer Lett; 2005 Oct; 228(1-2):187-93. PubMed ID: 15953676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.